4. Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
5. For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
6. Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.
You may not be if
1. History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
2. Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
3. Unstable brain metastases.
4. Inability to comply with the study for any reason.
5. Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.
Clareo Health | Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
